SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- MatriSys Bioscience Inc., a clinical-stage specialty biopharmaceutical company developing microbiome-based therapies for the five most common skin diseases, has appointed longtime life science executive Jennifer Giottonini Cayer to its Board of Directors.
Ms. Cayer brings more than 25 years of leadership experience spanning biotech, pharmaceutical and medical devices. She co-founded several venture-funded biotech companies that were subsequently acquired by global pharmaceutical companies or became publicly traded. In addition, Ms. Cayer has executed many significant alliances with pharmaceutical and biotech companies worth over $5 billion, including mergers and acquisitions, drug licensing, technology licensing, drug discovery and development collaborations, and company spinouts.
“Jennifer’s significant experience and business acumen will add valuable depth and perspective to our board’s guidance as we advance clinical development of our pipeline,” said Mark S. Wilson, CEO of MatriSys Bioscience. “As MatriSys Bioscience moves toward commercialization of our technology, we will benefit greatly from the relevant experience and insights of entrepreneurial-minded life science leaders like Jennifer”.
Ms. Cayer is president and CEO of 3E Therapeutics, a clinical-stage migraine company based in San Diego. Prior to founding Travus Therapeutics and Chromis Therapeutics, Ms. Cayer was chief operating officer at Rempex Pharmaceuticals, which was acquired by The Medicines Co. two years later. She also co-founded Conatus Pharmaceuticals, where she served as Senior Vice President of Corporate Development and led negotiations for the acquisition of multiple drug candidates.
Earlier in her career, Ms. Cayer led corporate development for Idun Pharmaceuticals, playing a key role in negotiating the company’s acquisition by Pfizer. She also spent five years at Ionis Pharmaceuticals most recently as Vice President of Business Development, and held a variety of operational roles at Gensia and Puritan Bennett (Tyco). She is a member of the board of directors for Chromis Therapeutics and Biocom, and a member of Corporate Directors Forum. She holds a B.S. in Bioengineering from University of California, San Diego.
About MatriSys Bioscience
MatriSys Bioscience is a clinical-stage specialty biopharmaceutical company advancing a pipeline of topical microbiome-derived therapies for unmet dermatology indications. Founded in 2015, our novel approach is based on the landmark research of Richard L. Gallo, M.D., Ph.D., of University of California, San Diego, and his findings related to the five leading dermatology and skin care conditions (acne, atopic dermatitis, rosacea, psoriasis and skin infections), which together affect more than 230 million patients. Our lead program, MSB-01, harnesses the power of the “good bug” S. hominis A9 to treat atopic dermatitis. For more information, please visit http://www.matrisysbio.com/.
Mark S. Wilson
Co-founder and CEO
mwilson@matrisysbio.com